TY - JOUR
T1 - The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy
AU - Peintinger, Florentia
AU - Symmans, W. Fraser
AU - Gonzalez-Angulo, Ana M.
AU - Boughey, Judy C.
AU - Buzdar, Aman U.
AU - Yu, T. Kuan
AU - Hunt, Kelly K.
AU - Singletary, S. Eva
AU - Babiera, Gildy V.
AU - Lucci, Anthony
AU - Meric-Bernstam, Funda
AU - Kuerer, Henry M.
PY - 2006/9/15
Y1 - 2006/9/15
N2 - BACKGROUND. The objectives of this study were to determine the locoregional recurrence (LRR) rate and to evaluate the correlation between surgical resection volume (RV) and LRR in patients with breast cancer who underwent segmental mastectomy after achieving a pathologic complete response (pCR) on neoadjuvant chemotherapy. METHODS. We reviewed the outcomes of all 109 patients who underwent segmental mastectomy after the complete eradication of invasive disease by neoadjuvant chemotherapy at their institution between 1987 and 2002. LRRs were recorded, and RVs after segmental mastectomy were calculated and categorized as small, medium, or large. RESULTS. At a median follow-up of 6.6 years, 3 patients (2.7%) developed LRR. In 2 of those patients, the recurrence was located in the ipsilateral breast; in the other patient, the recurrence was located in the supraclavicular lymph nodes with synchronous distant metastases. The median RV was 73.12 cm3 (range, 2.82-451.51 cm3). Large RVs (>125 cm3) were less common than small RVs (up to 70 cm3) or medium RVs (between 70 cm3 and 125 cm3; P =.009 and P < .0001, respectively). One patient with a small RV had an LRR at 4 years, and 2 patients with medium RVs had LLRs at 2.3 years and 6 years, respectively. The 5-year and 10-year LRR-free survival rates were 98.1% and 96.5%, respectively, and the corresponding overall survival rates were 96% and 92%, respectively. CONCLUSIONS. Segmental mastectomy was associated with excellent locoregional control in patients who achieved a pCR after neoadjuvant chemotherapy. Prospective studies are needed to examine whether decreasing the RVs in this patient population leads to an increased LRR rate.
AB - BACKGROUND. The objectives of this study were to determine the locoregional recurrence (LRR) rate and to evaluate the correlation between surgical resection volume (RV) and LRR in patients with breast cancer who underwent segmental mastectomy after achieving a pathologic complete response (pCR) on neoadjuvant chemotherapy. METHODS. We reviewed the outcomes of all 109 patients who underwent segmental mastectomy after the complete eradication of invasive disease by neoadjuvant chemotherapy at their institution between 1987 and 2002. LRRs were recorded, and RVs after segmental mastectomy were calculated and categorized as small, medium, or large. RESULTS. At a median follow-up of 6.6 years, 3 patients (2.7%) developed LRR. In 2 of those patients, the recurrence was located in the ipsilateral breast; in the other patient, the recurrence was located in the supraclavicular lymph nodes with synchronous distant metastases. The median RV was 73.12 cm3 (range, 2.82-451.51 cm3). Large RVs (>125 cm3) were less common than small RVs (up to 70 cm3) or medium RVs (between 70 cm3 and 125 cm3; P =.009 and P < .0001, respectively). One patient with a small RV had an LRR at 4 years, and 2 patients with medium RVs had LLRs at 2.3 years and 6 years, respectively. The 5-year and 10-year LRR-free survival rates were 98.1% and 96.5%, respectively, and the corresponding overall survival rates were 96% and 92%, respectively. CONCLUSIONS. Segmental mastectomy was associated with excellent locoregional control in patients who achieved a pCR after neoadjuvant chemotherapy. Prospective studies are needed to examine whether decreasing the RVs in this patient population leads to an increased LRR rate.
KW - Breast-conserving surgery
KW - Neoadjuvant chemotherapy
KW - Pathologic complete response
KW - Segmental mastectomy
UR - http://www.scopus.com/inward/record.url?scp=33748998192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748998192&partnerID=8YFLogxK
U2 - 10.1002/cncr.22111
DO - 10.1002/cncr.22111
M3 - Review article
C2 - 16862596
AN - SCOPUS:33748998192
SN - 0008-543X
VL - 107
SP - 1248
EP - 1254
JO - Cancer
JF - Cancer
IS - 6
ER -